Skip to main content
OpenTrials
Completed

NCT Number: NCT01693744

Pseudoexfoliation and Chronic Kidney Disease

Background: Pseudoexfoliation (PEX) is characterised by the deposition of fibrillar material in an eye structures and many other parts of the body including kidneys and blood vessels. As both PEX and chronic kidney disease (CKD) are associated with oxidative stress and endothelial dysfunction we studied if the risk of PEX was increased in patients with CKD.

Methods: Patients over age 40 with the diagnosis of CKD were included in the study. Chronic kidney disease was diagnosed as decreased glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m². Study groups were arranged as group 1 consisting of HD receiving patients, group 2 consisting of stage 1-4 CKD patients and group 3 consisting of patients with normal kidney functions (control group). Demographic properties and the rate of PEX were evaluated and compaired between the groups.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients with chronic kidney disease stage 1-5

Exclusion criteria

  • History of eye trauma or surgery

Treatment and study plan

Primary outcomes

  1. Prevalance of pseudoexfoliation in patients with chronic kidney disease

    Time frame: 7 months

Sponsors and collaborators

Lead sponsor

Corum State Hospital

Other

Registry information

Official study title

The Relationship Between Pseudoexfoliation and Chronic Kidney Disease

Important dates

Study start
2011
Study completion
2012
First posted
Sep 26, 2012
Registry last updated
Sep 26, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.